Molecular diagnostic company, Signal Genetics, has agreed to merge with Miragen Therapeutics (miRagen) to form a biopharmaceutical company that will develop proprietary micro RNA-targeted therapeutics for haematological malignancies and pathological fibrosis and cardiovascular and neurodegenerative diseases.
Pursuant to the definitive merger agreement, the stockholders of miRagen will hold 96% of Signal’s outstanding common stock on a fully-diluted basis, subject to certain approvals.
Go deeper with GlobalData
Health care informatics company, Karos Health, will be acquired by Vital Images allowing the companies to offer robust imaging and informatics solution set to their customers and OEM partners.
In a move to expand its business in extracorporeal organ support area, dialysis-related products and services provider, Fresenius Medical Care (FMC), has announced its intention to acquire Xenios from ZFHN Zukunftsfonds Heilbronn GmbH, a private venture capitalist based in Germany.
Xenios develops minimally invasive devices for lung and heart diseases.
See Also:
The deal will be completed before the end of 2016, subject to cartel authority approvals.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
